Refractory Multiple Myeloma - Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Refractory Multiple Myeloma - Pipeline Review, H2 2012', provides an overview of the Refractory Multiple Myeloma therapeutic pipeline. This report provides information on the therapeutic development for Refractory Multiple Myeloma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma. 'Refractory Multiple Myeloma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
Reasons to buy
Keywords
Refractory Multiple Myeloma Therapeutic Products under Development, Key Players in Refractory Multiple Myeloma Therapeutics, Refractory Multiple Myeloma Pipeline Overview, Refractory Multiple Myeloma Pipeline, Refractory Multiple Myeloma Pipeline Assessment
Summary
Global Markets Direct’s, 'Refractory Multiple Myeloma - Pipeline Review, H2 2012', provides an overview of the Refractory Multiple Myeloma therapeutic pipeline. This report provides information on the therapeutic development for Refractory Multiple Myeloma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma. 'Refractory Multiple Myeloma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Refractory Multiple Myeloma.
- A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Refractory Multiple Myeloma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Refractory Multiple Myeloma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Refractory Multiple Myeloma Therapeutic Products under Development, Key Players in Refractory Multiple Myeloma Therapeutics, Refractory Multiple Myeloma Pipeline Overview, Refractory Multiple Myeloma Pipeline, Refractory Multiple Myeloma Pipeline Assessment
Introduction
Global Markets Direct Report Coverage
Refractory Multiple Myeloma Overview
Therapeutics Development
An Overview of Pipeline Products for Refractory Multiple Myeloma
Refractory Multiple Myeloma Therapeutics under Development by Companies
Refractory Multiple Myeloma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Refractory Multiple Myeloma Therapeutics – Products under Development by Companies
Refractory Multiple Myeloma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Refractory Multiple Myeloma Therapeutics Development
Bristol-Myers Squibb Company
Abbott Laboratories
Eli Lilly and Company
Merck & Co., Inc.
Piramal Healthcare Limited
Millennium Pharmaceuticals, Inc.
Cephalon, Inc.
ImmunoGen, Inc.
Pfizer Inc.
Celgene Corporation
Onyx Pharmaceuticals, Inc.
EntreMed, Inc.
AEterna Zentaris Inc.
Array BioPharma Inc.
Threshold Pharmaceuticals, Inc.
Acetylon Pharmaceuticals, Inc.
Refractory Multiple Myeloma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ENMD-2076 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-833923 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kyprolis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kyprolis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TH-302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-936564 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P276 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aflibercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zolinza + Revlimid + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PD 0332991 + Velcade + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dasatinib + Velcade + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sprycel + Revlimid + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Treanda + Velcade - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Perifosine + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revlimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actimid + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Perifosine + Lenalidomide + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Velcade + Tipifarnib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + CC-4047 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMGN901 + Revlimid + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Bortezomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Decadron + Biaxin + CC-4047 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bendamustine + CC-5013 + Dexamethasone + Aspirin + H-2 blocker + Diflucan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Busulfan + Melphalan + Dexamethasone + Palifermin + Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC 4047 + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MLN9708 + Lenalidomide + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARRY-520 + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACY-1215 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carfilzomib + Lenalidomide + Vorinostat + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACY-1215 + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TH-302 + Bortezomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEP-18770 + Lenalidomide + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amrubicin + Lenalidomide + Dexamethasone + Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-936564 + Revlimid + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-936564 + Velcade + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2127399 + Bortezomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARRY-520 + Bortezomib + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Elotuzumab + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pomalidomide + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine Phosphate + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil + Allogeneic Hematopoietic Stem Cell Transplantation + Yttrium Y 90 Anti-cd45 Monoclonal Antibody Bc8 + Total-Body Irradiation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Refractory Multiple Myeloma Therapeutics – Drug Profile Updates
Refractory Multiple Myeloma Therapeutics – Discontinued Products
Refractory Multiple Myeloma Therapeutics - Dormant Products
Refractory Multiple Myeloma – Product Development Milestones
Featured News & Press Releases
Jul 02, 2012: Onyx Pharma Initiates Phase III Kyprolis Head-To-Head Comparison Trial Versus Velcade In Patients With Relapsed Multiple Myeloma
Jun 28, 2012: Millennium Initiates Phase III Trial Of MLN9708 In Patients With Relapsed And/Or Refractory Multiple Myeloma
Jun 21, 2012: Celgene's NDA For Pomalidomide And Dexamethasone Combination Therapy Accepted For Standard Review By FDA
Jun 05, 2012: Aeterna Zentaris Announces Publication Of Phase I Data For Perifosine In Multiple Myeloma In British Journal Of Hematology
Apr 26, 2012: Onyx Pharma Announces FDA Advisory Committee To Review Carfilzomib For Treatment Of Patients With Relapsed And Refractory Multiple Myeloma
Jun 07, 2011: Onyx Pharma Announces Data Presentations On Carfilzomib At 16th Congress Of European Hematology Association
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Refractory Multiple Myeloma, H2 2012
Products under Development for Refractory Multiple Myeloma – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Bristol-Myers Squibb Company, H2 2012
Abbott Laboratories, H2 2012
Eli Lilly and Company, H2 2012
Merck & Co., Inc., H2 2012
Piramal Healthcare Limited, H2 2012
Millennium Pharmaceuticals, Inc., H2 2012
Cephalon, Inc., H2 2012
ImmunoGen, Inc., H2 2012
Pfizer Inc., H2 2012
Celgene Corporation, H2 2012
Onyx Pharmaceuticals, Inc., H2 2012
EntreMed, Inc., H2 2012
AEterna Zentaris Inc., H2 2012
Array BioPharma Inc., H2 2012
Threshold Pharmaceuticals, Inc., H2 2012
Acetylon Pharmaceuticals, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Refractory Multiple Myeloma Therapeutics – Drug Profile Updates
Refractory Multiple Myeloma Therapeutics – Discontinued Products
Refractory Multiple Myeloma Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Refractory Multiple Myeloma, H2 2012
Products under Development for Refractory Multiple Myeloma – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Global Markets Direct Report Coverage
Refractory Multiple Myeloma Overview
Therapeutics Development
An Overview of Pipeline Products for Refractory Multiple Myeloma
Refractory Multiple Myeloma Therapeutics under Development by Companies
Refractory Multiple Myeloma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Refractory Multiple Myeloma Therapeutics – Products under Development by Companies
Refractory Multiple Myeloma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Refractory Multiple Myeloma Therapeutics Development
Bristol-Myers Squibb Company
Abbott Laboratories
Eli Lilly and Company
Merck & Co., Inc.
Piramal Healthcare Limited
Millennium Pharmaceuticals, Inc.
Cephalon, Inc.
ImmunoGen, Inc.
Pfizer Inc.
Celgene Corporation
Onyx Pharmaceuticals, Inc.
EntreMed, Inc.
AEterna Zentaris Inc.
Array BioPharma Inc.
Threshold Pharmaceuticals, Inc.
Acetylon Pharmaceuticals, Inc.
Refractory Multiple Myeloma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ENMD-2076 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-833923 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kyprolis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kyprolis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TH-302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-936564 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P276 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aflibercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zolinza + Revlimid + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PD 0332991 + Velcade + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dasatinib + Velcade + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sprycel + Revlimid + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Treanda + Velcade - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Perifosine + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revlimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actimid + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Perifosine + Lenalidomide + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Velcade + Tipifarnib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + CC-4047 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMGN901 + Revlimid + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Bortezomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Decadron + Biaxin + CC-4047 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bendamustine + CC-5013 + Dexamethasone + Aspirin + H-2 blocker + Diflucan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Busulfan + Melphalan + Dexamethasone + Palifermin + Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC 4047 + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MLN9708 + Lenalidomide + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARRY-520 + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACY-1215 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carfilzomib + Lenalidomide + Vorinostat + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACY-1215 + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TH-302 + Bortezomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEP-18770 + Lenalidomide + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amrubicin + Lenalidomide + Dexamethasone + Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-936564 + Revlimid + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-936564 + Velcade + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2127399 + Bortezomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARRY-520 + Bortezomib + G-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Elotuzumab + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pomalidomide + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine Phosphate + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil + Allogeneic Hematopoietic Stem Cell Transplantation + Yttrium Y 90 Anti-cd45 Monoclonal Antibody Bc8 + Total-Body Irradiation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Refractory Multiple Myeloma Therapeutics – Drug Profile Updates
Refractory Multiple Myeloma Therapeutics – Discontinued Products
Refractory Multiple Myeloma Therapeutics - Dormant Products
Refractory Multiple Myeloma – Product Development Milestones
Featured News & Press Releases
Jul 02, 2012: Onyx Pharma Initiates Phase III Kyprolis Head-To-Head Comparison Trial Versus Velcade In Patients With Relapsed Multiple Myeloma
Jun 28, 2012: Millennium Initiates Phase III Trial Of MLN9708 In Patients With Relapsed And/Or Refractory Multiple Myeloma
Jun 21, 2012: Celgene's NDA For Pomalidomide And Dexamethasone Combination Therapy Accepted For Standard Review By FDA
Jun 05, 2012: Aeterna Zentaris Announces Publication Of Phase I Data For Perifosine In Multiple Myeloma In British Journal Of Hematology
Apr 26, 2012: Onyx Pharma Announces FDA Advisory Committee To Review Carfilzomib For Treatment Of Patients With Relapsed And Refractory Multiple Myeloma
Jun 07, 2011: Onyx Pharma Announces Data Presentations On Carfilzomib At 16th Congress Of European Hematology Association
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products Under Development for Refractory Multiple Myeloma, H2 2012
Products under Development for Refractory Multiple Myeloma – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Bristol-Myers Squibb Company, H2 2012
Abbott Laboratories, H2 2012
Eli Lilly and Company, H2 2012
Merck & Co., Inc., H2 2012
Piramal Healthcare Limited, H2 2012
Millennium Pharmaceuticals, Inc., H2 2012
Cephalon, Inc., H2 2012
ImmunoGen, Inc., H2 2012
Pfizer Inc., H2 2012
Celgene Corporation, H2 2012
Onyx Pharmaceuticals, Inc., H2 2012
EntreMed, Inc., H2 2012
AEterna Zentaris Inc., H2 2012
Array BioPharma Inc., H2 2012
Threshold Pharmaceuticals, Inc., H2 2012
Acetylon Pharmaceuticals, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Refractory Multiple Myeloma Therapeutics – Drug Profile Updates
Refractory Multiple Myeloma Therapeutics – Discontinued Products
Refractory Multiple Myeloma Therapeutics – Dormant Products
LIST OF FIGURES
Number of Products under Development for Refractory Multiple Myeloma, H2 2012
Products under Development for Refractory Multiple Myeloma – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
